Shares of Emcure Pharmaceuticals came under pressure on Monday after a social media controversy involving its Executive Director, Namita Thapar. The stock fell despite a broader market rally, reflecting investor concern over the ongoing backlash online.
At the time of writing, Emcure Pharma shares were down 2.64% at Rs 1,628.
The issue began with a towards the end of March. In the reel, she spoke about the health benefits of Namaz, describing it as a form of full-body exercise.
She highlighted that the practice can support digestion, improve flexibility, and help with mental well-being. She also pointed out that the meditative and repetitive nature of Namaz may benefit mental health. According to her, the Vajrasana posture, which is part of the practice, can aid digestion and offer a moment of calm in a busy day.
The video soon went viral, but it also attracted criticism and trolling on social media. Some users reacted strongly to her comments, leading to a wider online debate.
On Monday, . She said she had earlier shared similar content on Hindu practices as well.
While the broader market remained positive, Emcure Pharma’s stock moved in the opposite direction. The decline suggests that investors are closely watching developments, as reputational issues can sometimes impact sentiment in the short term.
For now, the situation highlights how quickly social media reactions can spill over into market movements, especially when senior company leaders are involved.